ORPHA:480483
Progressive familial intrahepatic cholestasis type 4
Also known as: PFIC4 · TJP2 deficit
Publications
1,882
Trials
0
Interventional, condition-specific
Researchers
412
Distinct authors in sample
Gene link
TJP2
Strong
Readiness
5/6
Stages with a signal
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014381
- OMIM:615878
- UMLS:C2931067
Additional Mondo synonyms (5)
TJP2 progressive familial intrahepatic cholestasis · cholestasis, progressive familial intrahepatic, 4 · cholestasis, progressive familial intrahepatic, type 4 · progressive familial intrahepatic cholestasis caused by mutation in TJP2 · progressive familial intrahepatic cholestasis type 4
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Strong — TJP2
- LiteraturePresent
1,882 matched papers (1,355 in last 10 years) Source
- Phenotype characterisedPresent
5 HPO annotations (e.g. Hepatic failure; Portal hypertension; Cirrhosis) Source
- Animal modelPresent
1 genotype model (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 12 for broader category progressive familial intrahepatic cholestasis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (TJP2).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
5
Associated phenotypes · MONDO:0014381
- Hepatic failure
- Portal hypertension
- Cirrhosis
- Intrahepatic cholestasis
- Hepatocellular carcinoma
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- Tjp1tm1.1Whun/Tjp1tm1.1Whun Tjp2tm2Whun/Tjp2tm2Whun Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ [background:] involves: 129S6/SvEvTac * C57BL/6 * C57BL/6N * C57BL/6NTac * DBA/2·MGI:6719082·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,882
1,882 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,882 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,355 in the last 10 years · low confidence
Phrase hits: 76 · MeSH hits: 0
Who's working on it?
412
Distinct author names in 76 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Vitale G4 papers · 2025
ITEC Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy; Research Centre for the Study of Hepatitis, University of Bologna, Italy; End-stage Liver Disease Unit, Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, University of Bologna, Italy.
Papers in Europe PMC - 02Anakk S2 papers · 2019
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois.
Papers in Europe PMC - 03Andreone P2 papers · 2019
ITEC Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy; Research Centre for the Study of Hepatitis, University of Bologna, Italy. Electronic address: pietro.andreone@unibo.it.
Papers in Europe PMC - 04Arizpe A2 papers · 2019
School of Natural Science, University of Texas at Austin, Austin, Texas.
Papers in Europe PMC - 05Choi JM2 papers · 2019
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Papers in Europe PMC - 06Cirillo F2 papers · 2026
Pediatric Hepatology and Paediatric Liver Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, 90127 Palermo, Italy.
Papers in Europe PMC - 07Drozdzik M2 papers · 2024
Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Papers in Europe PMC - 08Elmonem MA2 papers · 2026
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. mohamed.abdelmonem@kasralainy.edu.eg.
Papers in Europe PMC - 09Fabre A2 papers · 2024
Pediatric Gastroenterology, Hepatology and Nutrition Unit, Marseille University Hospital, 13288 Marseille, France.
Papers in Europe PMC - 10Gitto S2 papers · 2019
ITEC Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy; Research Centre for the Study of Hepatitis, University of Bologna, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 12 trials are registered for progressive familial intrahepatic cholestasis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
12 interventional trials matched progressive familial intrahepatic cholestasis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: progressive familial intrahepatic cholestasis
12
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07290257·RECRUITING·Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Conditions: Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
- NCT07317193·RECRUITING·DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE
Conditions: Cholestatic Liver Disease · Progressive Familial Intrahepatic Cholestasis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Progressive familial intrahepatic cholestasis type 4 — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Progressive familial intrahepatic cholestasis type 4" OR "PFIC4" OR "TJP2 deficit" OR "TJP2 progressive familial intrahepatic cholestasis" OR "cholestasis, progressive familial intrahepatic, 4" OR "cholestasis, progressive familial intrahepatic, type 4" OR "progressive familial intrahepatic cholestasis caused by mutation in TJP2") OR ("TJP2" OR "TJP2 syndrome" OR "TJP2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Progressive familial intrahepatic cholestasis type 4" OR "PFIC4" OR "TJP2 deficit" OR "TJP2 progressive familial intrahepatic cholestasis" OR "cholestasis, progressive familial intrahepatic, 4" OR "cholestasis, progressive familial intrahepatic, type 4" OR "progressive familial intrahepatic cholestasis caused by mutation in TJP2"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"progressive familial intrahepatic cholestasis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1882) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T17:12:16.372Z
